memo-inOncology – SPECIAL ISSUE

Find out the latest news from international oncology congresses and stay at the forefront of clinical innovation and advances in lung cancer research.

The memo inOncology Medical education series: keeping oncologists at the forefront of lung cancer research. memo – inOncology Special Issue Preceptorship reports summarise the latest in lung cancer research and treatments to come out of our sponsored Preceptorship meeting series. The Fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.

Latest congress reports


Get a notification for every published memo – inOncology SPECIAL ISSUE. Register below.


    ASH 2022 Cover

    memo – inOncology SPECIAL ISSUE

    Congress Report ASH 2022

    Report from the American Society of Hematology (ASH) Annual Meeting,
    10th – 13th December 2022, hybrid congress

    Now available!

    NANETS 2022 Cover

    memo – inOncology SPECIAL ISSUE

    Congress Report NANETS 2022

    Report from the North American Neuroendocrine Tumor Society (NANETS) Annual Medical Symposium,
    October 27th–29th 2022, Washington

    Now available!

    EANM 2022 Cover

    memo – inOncology SPECIAL ISSUE

    Congress Report EANM 2022

    Report from the European Association of Nuclear Medicine (EANM) 35th Annual Congress,
    October 15th–19th 2022, Barcelona

    Now available!



    All videointerviews from ASH 2022

    Shirley D’Sa discusses the results of the first clinical trial investigating checkpoint inhibition in relapsed/refractory Waldenström’s macroglobulinemia as well as other immunotherapeutic agents or combinations that might be worth investigating in this setting and explains the association of type I cryoglobulinemia with WM, IgM monoclonal gammopathy of undetermined significance or non-Hodgkin Lymphoma.


    All videointerviews from ASCO Lung Cancer 2022

    Jessica Donington highlights the most promising agents currently investigated in the neoadjuvant setting in patients with resectable NSCLC, how the “intensity” of neoadjuvant treatment affects the outcomes and discusses if neoadjuvant chemo-immunotherapy is the new standard of care. She outlines which variables related to surgery itself are determinants of the success of curative surgery and which biomarkers are on the rise to guide therapy.

    John Varlotto summarizes the insights that have been obtained based on recent studies regarding immunotherapy plus chemoradiation in patients with unresectable, locally advanced stage III non-small cell lung cancer, explains the different effect observed with pembrolizumab and nivolumab and how these results compare to existing data. He cautions against using the impressive pathologic complete response rates with neoadjuvant chemoimmunotherapy to the unresectable setting due to the lack of long-term survival rates with neo-adjuvant chemo/immunotherapy and the impressive 47.5 median overall survival noted with concurrent chemo/radiotherapy followed by consolidative durvalumab in the Pacific Trial.



    For Oncologists and Haematologists